A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of a Single Dose of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Latest Information Update: 26 Jun 2019
At a glance
- Drugs Bimagrumab (Primary)
- Indications Cachexia; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Aug 2018 Results (n=67) published in the American Journal of Respiratory and Critical Care Medicine.
- 18 May 2016 Primary endpoint has been met. (Change in thigh muscle volume compare to placebo as measured by MRI), as per an abstract presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society